Mach7 Technologies

Mach7 Technologies Debt/EBITDA

The Total Debt to EBITDA Ratio of Mach7 Technologies (M7T.AX) as of Oct 30, 2026 is -0.01. In the previous year, Total Debt to EBITDA Ratio was -0.95 — a change of -98.90% (higher).

Debt/EBITDA

-0.01

YoY

-98.90%

Last updated:

Total Debt to EBITDA Ratio of Mach7 Technologies is 2026 -0.01 . Total Debt to EBITDA Ratio of Mach7 Technologies was 2025 -0.95 . It decreases by -98.90% higher compared to the previous year.

The Mach7 Technologies Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
-0.15 AUD
Jan 1, 2020
0.11 AUD
Jan 1, 2021
-0.69 AUD
Jan 1, 2022
0.65 AUD
Jan 1, 2023
0.92 AUD
Jan 1, 2024
-0.45 AUD
Jan 1, 2025
-0.95 AUD
Jan 1, 2026
-0.01 AUD
The Mach7 Technologies Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.01-98.90%
-0.95+112.27%
-0.45-148.60%
0.92+41.53%
0.65-194.03%
-0.69-756.96%
0.11-170.27%
-0.15+4,420.75%
-0.00+114.73%
-0.00-99.81%
-0.80-58.77%
-1.93—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mach7 Technologies Stock analysis

What does Mach7 Technologies do? Mach7 Technologies Ltd. generates revenue through its medical imaging software and services for healthcare institutions. The company offers the Mach7 Enterprise Imaging Solution, which includes Enterprise Data Management, Enterprise Diagnostic Viewing, and Departmental Workflow applications. Enterprise Data Management features a Vendor Neutral Archive (VNA) and data administration tools for fast storage, access, retrieval, and viewing of images across healthcare networks with cloud connectivity. Enterprise Diagnostic Viewing provides consolidated access to patient images and data for healthcare professionals, enabling timely diagnosis and treatment. The company serves global healthcare enterprises across North America, Asia Pacific, and the Middle East regions. Mach7 Technologies Ltd. targets healthcare institutions as its primary customers, including hospitals and medical facilities that require advanced imaging and data management solutions. The core products, Mach7 Enterprise Imaging Solution and its components, are sold to these institutions to streamline workflows and improve patient care. The company's focus on global healthcare enterprises ensures a broad market reach in key regions, supporting its revenue streams through software licensing and service contracts. The principal activity of Mach7 Technologies Ltd. is the development and commercialization of medical imaging and data management software solutions. The firm's offerings are designed to meet the needs of healthcare enterprises by providing integrated tools for image storage, access, and diagnostic viewing. By focusing on the North America, Asia Pacific, and Middle East regions, the company capitalizes on the growing demand for efficient healthcare data management systems, driving sales of its software solutions to healthcare institutions. Mach7 Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mach7 Technologies stock

Total Debt to EBITDA Ratio of Mach7 Technologies is -0.01 in 2026.

Total Debt to EBITDA Ratio of Mach7 Technologies changed from -0.95 to -0.01, representing a -98.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Mach7 Technologies since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Mach7 Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Mach7 Technologies

All Key Metrics — Mach7 Technologies